TLPH

Talphera, Inc. (TLPH) | Rumor.io

Talphera

TLPH

Attention (50-day avg)0%

Attention rank (50-day avg)#3,113

Bullish sentiment (50-day avg)56%

Price to earnings ratio-3.51

Market capitalization61.8M

Earnings per share-0.23

Dividend yield (TTM)—

Revenue (annual)28K

Net income (annual)-14.3M

Social

What share of all stock conversation is about TLPH?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Aug 12

TLPH disclosed 75% enrollment in the NEPHRO-CRRT trial, with an expected completion by the end of the year.
CRMD has an exclusive option to negotiate an acquisition of TLPH if the primary endpoint is met in the NEPHRO-CRRT trial.
TLPH reported GAAP EPS of -$0.06, a 40% YoY increase, and 75% enrollment in the NEPHRO-CRRT trial.

Generated by AI

Sentiment

Of the messages about TLPH that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	0%	0% -71.43	91.91% +2.77
Bearish	—	100%	100% +71.43	8.09% -2.77

Bullish· Nov 12

Talphera's Phase 3 Niyad kidney treatment update is expected to be reported after the bell, with potential for a positive readout and a subsequent buyout by CRMD.
CRMD's CEO is now on the Talphera Board, with CRMD owning 20% of Talphera shares outstanding and the first right to acquire the company, indicating a strategic investment in Talphera's future.
Talphera's strong cash position and CRMD's significant investment in the company suggest that the asset has a high potential for growth and a likely increase in value in the coming weeks.

Bearish· Aug 19

The CEO and board of Talphera, Inc. are accused of engaging in a pump and dump scheme that has hurt investors.
The company's financials are expected to be weak, with a projected Q3 EPS of -0.13.
The stock's price is predicted to continue falling, potentially reaching as low as $1, as it is seen as a typical example of a pump and dump scheme.

Generated by AI

Topics

Of the messages about TLPH that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	80.69%
Analysts	—	—	—	0.69%
Controversies	—	—	—	0%
Earnings	—	—	—	1.38%
Macro	—	—	—	0%
Technical Analysis	—	—	—	17.24%

Controversies· Oct 12

The FDA Advisory Committee has recommended approval of DSUVIA, a pain reliever developed by ACRX, for the treatment of moderate-to-severe acute pain.
The approval recommendation was made despite concerns raised by some committee members about the safety and efficacy of the drug, including the risk of dropped tablets.
The controversy surrounding the approval process has led to accusations of corruption and conflicts of interest among some committee members.

Technical Analysis· Nov 5

$TLPH may test its high of day (HOD) after bouncing near $4.00.
The 50-day moving average is a key level of support for $TLPH, with one trade holding a buy at $4.32.
$TLPH's technical indicators, including RSI and MACD, are showing signs of a potential reversal, with a possible dip and rip higher.

Generated by AI

Community

Of the messages about TLPH, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	87.5%	69.76%
Newcomers	—	100%	12.5%	30.24%

Sep 8

The posts highlight the stock's recent price increase, with some users noting a +33% gain and others referencing a strong intraday breakout with high volume.
Newcomers to the stock are discussing the company's equity plan amendments, which they believe will align incentives for growth and attract traders.
The biotech sector's momentum is being watched by some users, who are anticipating potential catalysts for further growth, and others are discussing the company's phase 3 study results and potential acquisition by CorMedix.

Generated by AI

News

Talphera (TLPH) Upgraded to Buy: Here's What You Should Know

8d agoYahoo Finance

Talphera at H.C. Wainwright conference: nafamostat path gains traction

15d agoInvesting.com

Talphera (TLPH) Q2 2026 Earnings Call Transcript

Motley Fool Press Release.

1mo agoThe Globe and Mail

Analysts Offer Insights on Healthcare Companies: Dogwood Therapeutics (DWTX), Talphera (TLPH) and 4D Molecular Therapeutics (FDMT)

Detailed price information for Dogwood Therapeutics Inc (DWTX-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Talphera, Inc. Q2 2026 Earnings Call Summary

Moby summary of Talphera, Inc.'s Q2 2026 earnings call

1mo agoYahoo Finance

H.C. Wainwright reiterates Talphera stock rating on trial progress

1mo agoInvesting.com

Also Discussed

Investors talking about TLPH also mention

#	Name	Attention
1	TRVN - Trevena, Inc.	——
2	Catalyst Pharmaceuticals Inc.CPRX	0%new
3	CorMedix Inc.CRMD	0%+0
4	Fresenius Medical Care AG - Depositary ReceiptFMS	0%new
5	Verastem Inc.VSTM	0%0
6	DaVita Inc.DVA	0%new
7	Amarin Corporation plc ADRAMRN	0%+0
8	TTNP - Titan Pharmaceuticals, Inc.	——
9	TTSH - Tile Shop Holdings, Inc.	——
10	ONCT - Oncternal Therapeutics, Inc.	——

Talphera, Inc.

Healthcare
Drug Manufacturers - Specialty & Generic

Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapies for use in medically supervised settings. The company’s current portfolio centers on nafamostat product candidates and pre-filled syringe products designed for acute care environments, including hospital and procedural settings. Its lead program, Niyad, is a lyophilized formulation of nafamostat being studied as a regional anticoagulant for the extracorporeal circuit, while its broader pipeline includes pre-filled syringe products such as ephedrine and phenylephrine formulations. Talphera serves healthcare providers by targeting needs in high-acuity care where reliable, ready-to-use therapies can support treatment workflows. Headquartered in San Mateo, California, Talphera remains focused on specialty pharmaceuticals for medically supervised use.

Website

Location

1850 Gateway Drive

San Mateo, CA, 94404

United States

Social

What share of all stock conversation is about TLPH?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Aug 12

TLPH disclosed 75% enrollment in the NEPHRO-CRRT trial, with an expected completion by the end of the year.
CRMD has an exclusive option to negotiate an acquisition of TLPH if the primary endpoint is met in the NEPHRO-CRRT trial.
TLPH reported GAAP EPS of -$0.06, a 40% YoY increase, and 75% enrollment in the NEPHRO-CRRT trial.

Generated by AI

Sentiment

Of the messages about TLPH that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	0%	0% -71.43	91.91% +2.77
Bearish	—	100%	100% +71.43	8.09% -2.77

Bullish· Nov 12

Talphera's Phase 3 Niyad kidney treatment update is expected to be reported after the bell, with potential for a positive readout and a subsequent buyout by CRMD.
CRMD's CEO is now on the Talphera Board, with CRMD owning 20% of Talphera shares outstanding and the first right to acquire the company, indicating a strategic investment in Talphera's future.
Talphera's strong cash position and CRMD's significant investment in the company suggest that the asset has a high potential for growth and a likely increase in value in the coming weeks.

Bearish· Aug 19

The CEO and board of Talphera, Inc. are accused of engaging in a pump and dump scheme that has hurt investors.
The company's financials are expected to be weak, with a projected Q3 EPS of -0.13.
The stock's price is predicted to continue falling, potentially reaching as low as $1, as it is seen as a typical example of a pump and dump scheme.

Generated by AI

Topics

Of the messages about TLPH that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	80.69%
Analysts	—	—	—	0.69%
Controversies	—	—	—	0%
Earnings	—	—	—	1.38%
Macro	—	—	—	0%
Technical Analysis	—	—	—	17.24%

Controversies· Oct 12

The FDA Advisory Committee has recommended approval of DSUVIA, a pain reliever developed by ACRX, for the treatment of moderate-to-severe acute pain.
The approval recommendation was made despite concerns raised by some committee members about the safety and efficacy of the drug, including the risk of dropped tablets.
The controversy surrounding the approval process has led to accusations of corruption and conflicts of interest among some committee members.

Technical Analysis· Nov 5

$TLPH may test its high of day (HOD) after bouncing near $4.00.
The 50-day moving average is a key level of support for $TLPH, with one trade holding a buy at $4.32.
$TLPH's technical indicators, including RSI and MACD, are showing signs of a potential reversal, with a possible dip and rip higher.

Generated by AI

Community

Of the messages about TLPH, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	87.5%	69.76%
Newcomers	—	100%	12.5%	30.24%

Sep 8

The posts highlight the stock's recent price increase, with some users noting a +33% gain and others referencing a strong intraday breakout with high volume.
Newcomers to the stock are discussing the company's equity plan amendments, which they believe will align incentives for growth and attract traders.
The biotech sector's momentum is being watched by some users, who are anticipating potential catalysts for further growth, and others are discussing the company's phase 3 study results and potential acquisition by CorMedix.

Generated by AI

Talphera

Social

Aug 12

Bullish· Nov 12

Bearish· Aug 19

Controversies· Oct 12

Technical Analysis· Nov 5

Sep 8

Talphera (TLPH) Upgraded to Buy: Here's What You Should Know

Talphera at H.C. Wainwright conference: nafamostat path gains traction

Talphera (TLPH) Q2 2026 Earnings Call Transcript

Analysts Offer Insights on Healthcare Companies: Dogwood Therapeutics (DWTX), Talphera (TLPH) and 4D Molecular Therapeutics (FDMT)

Talphera, Inc. Q2 2026 Earnings Call Summary

H.C. Wainwright reiterates Talphera stock rating on trial progress

Also Discussed

Talphera, Inc.

Company Information

Location

Talphera (TLPH) Upgraded to Buy: Here's What You Should Know

Talphera at H.C. Wainwright conference: nafamostat path gains traction

Talphera (TLPH) Q2 2026 Earnings Call Transcript

Analysts Offer Insights on Healthcare Companies: Dogwood Therapeutics (DWTX), Talphera (TLPH) and 4D Molecular Therapeutics (FDMT)

Talphera, Inc. Q2 2026 Earnings Call Summary

H.C. Wainwright reiterates Talphera stock rating on trial progress

Also Discussed

Social

Aug 12

Bullish· Nov 12

Bearish· Aug 19

Controversies· Oct 12

Technical Analysis· Nov 5

Sep 8